BNTC.US Benitec Biopharma Inc.

Healthcare Biotechnology USA Stocks
9.04 USD
Close of Nov 14, 2026
7.89 14.39
Market cap
USD 315M
P/E
-
P/B
1.80x
ROE
-30.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.

Is BNTC.US undervalued?

Graham number

The Graham number of Benitec Biopharma Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Benitec Biopharma Inc. fundamental analysis

No fundamental analysis for Benitec Biopharma Inc. yet.

Benitec Biopharma Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Benitec Biopharma Inc.

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The comp…

Full company profile